• Login
    View Item 
    •   ORKA Home
    • Conditions, Lifestyle Factors & Interventions
    • Conditions
    • Depressive Disorders
    • View Item
    •   ORKA Home
    • Conditions, Lifestyle Factors & Interventions
    • Conditions
    • Depressive Disorders
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Efficacy and acceptability of next step treatment strategies in adults with treatment-resistant major depressive disorder: protocol for systematic review and network meta-analysis

    Thumbnail
    View/Open
    Main article (366.3Kb)
    Date
    2022-04
    Author
    Cipriani, Andrea
    Metadata
    Show full item record
    Citation
    Muit JJ, van Eijndhoven PFP, Cipriani A, Dalhuisen I, van Bronswijk S, Furukawa TA, Ruhe HG. Efficacy and acceptability of next step treatment strategies in adults with treatment-resistant major depressive disorder: protocol for systematic review and network meta-analysis. BMJ Open. 2022 Apr 18;12(4):e056777
    Abstract
    For major depression, a one-size-fits-all treatment does not exist. Patients enter a ‘trial-and-change’ algorithm in which effective therapies are subsequently applied. Unfortunately, an empirically based order of treatments has not yet been determined. There is a magnitude of different treatment strategies while clinical trials only compare a small number of these. Network meta-analyses (NMA) might offer a solution, but so far have been limited in scope and did not account for possible differences in population characteristics that arise with increasing levels of treatment-resistance, potentially violating the transitivity assumption. We; therefore, present a protocol for a systematic review and NMA aiming at summarising and ranking treatments for treatment-resistant depression (TRD) while covering a broad range of therapeutic options and accounting for possible differences in population characteristics at increasing levels of treatment-resistance. Methods and analysis Randomised controlled trials will be included that compared next-step pharmacological, neuromodulation or psychological treatments for treatment-resistant depression (TRD; ie, failure to respond to ≥1 adequate antidepressant drug trial(s) in the current episode) to each other or to a control condition. Primary outcomes will be the proportion of patients who responded to (efficacy) and dropped out of (acceptability) the allocated treatment. A random effects NMA will be conducted, synthesising the evidence for each outcome and determining the differential efficacy of treatments. Heterogeneity in treatment nodes will be reduced by considering alternative geometries of the network structure and by conducting a meta-regression examining different levels of TRD. Local and global methods will be applied to evaluate consistency. The Cochrane Risk of Bias 2 tool, Confidence in Network Meta-Analysis and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework will be used to assess risk of bias and certainty.
    Description
    Open Access
    URI
    https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/1112
    Published online at:
    https://doi.org/10.1136%2Fbmjopen-2021-056777
    Collections
    • Depressive Disorders [91]

    Oxford Health copyright © 2019
    Contact Us | Send Feedback | JSPUI
    Powered by KnowledgeArc
     

     

    Browse

    All of ORKACommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsContributor DisciplineThis CollectionBy Issue DateAuthorsTitlesSubjectsContributor Discipline

    My Account

    Login

    Researcher Profiles

    Researchers

    Oxford Health copyright © 2019
    Contact Us | Send Feedback | JSPUI
    Powered by KnowledgeArc